Stakeholder perspectives on a risk-benefit framework for genetic testing

Public Health Genomics

Volumn 14, Issue 2, 2011, Pages 59-67

  Roth, Joshua A ^a   Garrison Jr , Louis P ^a   Burke, Wylie ^a   Ramsey, Scott D ^b   Carlson, Rick ^a   Veenstra, David L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Genetic testing; Pharmacogenomics; Quality adjusted life years; Risk benefit; Stakeholder; Warfarin

Indexed keywords

WARFARIN;

ARTICLE; DECISION MAKING; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUALITY ADJUSTED LIFE YEAR; RESEARCH PRIORITY; RISK BENEFIT ANALYSIS; WORKSHOP;

GENETIC TESTING; GENOMICS; GENOTYPE; HUMANS; PHARMACOGENETICS; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; TECHNOLOGY, PHARMACEUTICAL; UNCERTAINTY; WARFARIN;

EID: 79952453214     PISSN: 16624246     EISSN: None     Source Type: Journal    
DOI: 10.1159/000290452     Document Type: Article

References (25)

1. Holtzman NA, Watson MS: Promoting Safe and Effective Genetic Testing in the United States: Final Report of the Task Force on Genetic Testing. Baltimore, Johns Hopkins, 1998.
2. Garrison LP, Veenstra DL, Carlson RJ, Carlson J, Meckley L: Backgrounder on Pharmacogenomics for the Pharmaceutical and Biotechnology Industries: Basic Science, Future Scenarios, Policy Directions. University of Washington, Pharmaceutical Outcomes Research and Policy Program, 2007.
3. Garrison LP, Austin MJ: The economics of personalized medicine: a model of incentives for value creation and capture. Drug Inf J 2007; 41:501-509. (Pubitemid 47041921)
4. Lesko LJ: The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. Clin Pharmacol Ther 2008; 84: 301-303.
5. Garcia DA: Warfarin and pharmacogenomic testing: the case for restraint. Clin Pharmacol Ther 2008; 84: 303-305.
6. Evaluation of Genomic Applications in Practice and Prevention Working Group: Re commendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med 2009; 11: 66-73.
7. Tunis SR: Economic analysis in healthcare decisions. Am J Manag Care 2004; 10: 301-304. (Pubitemid 38623519)
8. Rogowski WH, Grosse SD, Khoury MJ: Challenges of translating genetic tests into clinical and public health practice. Genetics 2009; 10: 489-495.
9. Petitti DB, Teutsch SM, Barton MB, Sawaya GF, Ockene JK, De Witt T: Update on the methods of the U.S. Preventive Services Task Force: insufficient evidence. Ann Intern Med 2009; 150: 199-205.
10. Phillips KA, Veenstra DL, Sadee W: Implications of the genetics revolution for health services research: pharmacogenomics and improvements in drug therapy. Health Serv Res 2000; 35: 128-140.
11. Gurwitz JH, Field TS, Judge J, et al: The incidence of adverse drug events in two large academic long-term care facilities. Am J Med 2005; 118: 251-258. (Pubitemid 40312636)
12. Rieder MJ, Reiner AP, Gage BF, et al: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293. (Pubitemid 40740552)
13. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL: Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004; 91: 87-94. (Pubitemid 38111225)
14. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK: Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 2004; 14: 539-547. (Pubitemid 39100005)
15. Limdi NA, McGwin G, Goldstein JA, et al: Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European- American patients on warfarin. Clin Pharmacol Ther 2007; 83: 312-321.
16. Anderson JL, Horne BD, Stevens SM, et al: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007; 116: 2563-2570. (Pubitemid 350179221)
17. Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL: A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 2010; 28: 61-74.
18. Hsieh HF, Shannon SE: Three approaches to qualitative content analysis. Qual Health Res 2005; 15: 1277-1288. (Pubitemid 41645161)
19. Garrison LP, Towse A, Breshahan BW: Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Health Aff 2007; 26: 684-695.
20. Garrison LP, Mansley EC, Abbott TA, Bresnahan BW, Hay JW, Smeeding J: Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective. Value Health 2010; 13: 8-13.
21. Garrison LP: On the benefits of modeling using QALYs for societal resource allocation: the model is in the message. Value Health 2009; 12:S36-S37.
22. Neumann PJ, Greenberg D: Is the United States ready for QALYs? Health Aff 2009; 28: 1366-1371.
23. Johnson FR: Moving the QALY forward or just stuck in traffic? Value Health 2009; 12:S38-S39.
24. Kind P, Lafata JE, Matuszewski K, Raisch D: The use of QALYs in clinical and patient decision- making: issues and prospects. Value Health 2009; 12:S27-S30.
25. Grosse SD, McBride CM, Evans JP, Khoury MJ: Personal utility and genomic information: look before you leap. Genet Med 2009; 11: 575-576.